E89R
TEAS SECTION 8 & 9 RECEIVED
07/07/2026
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Snapshot rápido
SAMIRNA
ST13
US500000086287682Classe
Pedido
Registro
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Fundamento do pedido
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Titulares
Representantes
Jun-Hwa Jeong RABIN & BERDO, P.C.
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Diagnostic preparations for research use; Reagents for scientific research use; Chemicals for laboratory analyses, other than for medical use, namely, chemicals for use in biotechnological product development; Chemicals for pharmaceutical purposes, namely, for use in the manufacture of drugs and medicines; Chemicals for the manufacture of medical products in the nature of pharmaceutical preparations; Biochemicals, namely, biochemical reagents used for non-medical purposes; Chemical preparations for the manufacture of medical products
Classe 5
Pharmaceutical preparations for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Biological preparations for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Medicated vaccines and serums for treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Capsules sold empty for pharmaceutical purposes for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Microspheres containing pharmaceutical preparations, for treating cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Preparations and substances for facilitating delivery of pharmaceutical preparations, namely, drug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Carriers for drug delivery, namely, drug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Peptides for drug delivery, namely, drug delivery agents consisting of peptides attached to drugs that facilitate delivery of pharmaceutical preparations; Pharmaceutical preparations applied pharmaceutical drug delivery system, namely, elixirs for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies and a nanoparticle carrier for transferring siRNA in the cell or peptide; Chemical reagents for medical use; Pharmaceutical preparations for drug delivery into cells; Drug delivery formulations, namely, compositions consisting of nanoparticle for transferring siRNA in the cell or peptides; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purpose; Pharmaceutical preparations and substances for facilitating drug delivery in the form of nanoparticle for transferring siRNA in the cell or peptide for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing RNA for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing DNA for use in medical treatment via inhibition of gene expression
Classe 10
[ Drug delivery system; Implantable drug syringes for drug delivery devices; Implantable drug delivery pumps for drug delivery devices; Medical apparatus for introducing pharmaceutical preparations into the human body; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Injection device for pharmaceuticals; Microspheres, namely, unilaminar and bilaminar spherical particles comprising hydrophilic and hydrophobic polymers with diameters in the nanometer range used as a means for drug delivery for treating cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies ]
Classe 42
Pharmaceutical products research; Pharmaceutical products development; Research for medical products; Crude medicines research; Research and development of biotechnology for others; Quality control, namely, quality control of target gene expression activity with siRNA; Biotechnology research
Histórico de despachos e eventos da marca no USPTO.
44 publicações encontradas
TEAS SECTION 8 & 9 RECEIVED
07/07/2026
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
04/10/2025
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
05/10/2022
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
05/10/2022
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/10/2022
TEAS SECTION 8 RECEIVED
26/04/2022
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/10/2021
REGISTERED-PRINCIPAL REGISTER
04/10/2016
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/07/2016
PUBLISHED FOR OPPOSITION
19/07/2016
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/06/2016
LAW OFFICE PUBLICATION REVIEW COMPLETED
15/06/2016
APPROVED FOR PUB - PRINCIPAL REGISTER
08/06/2016
EXAMINER'S AMENDMENT ENTERED
08/06/2016
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/06/2016
EXAMINERS AMENDMENT E-MAILED
08/06/2016
EXAMINERS AMENDMENT -WRITTEN
08/06/2016
TEAS/EMAIL CORRESPONDENCE ENTERED
21/05/2016
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/05/2016
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/05/2016
NOTIFICATION OF PRIORITY ACTION E-MAILED
23/11/2015
PRIORITY ACTION E-MAILED
23/11/2015
PRIORITY ACTION WRITTEN
23/11/2015
DATA MODIFICATION COMPLETED
16/11/2015
ASSIGNED TO LIE
16/11/2015
ASSIGNED TO EXAMINER
09/11/2015
TEAS/EMAIL CORRESPONDENCE ENTERED
23/10/2015
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/10/2015
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
23/10/2015
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
21/08/2015
INQUIRY TO SUSPENSION E-MAILED
21/08/2015
SUSPENSION INQUIRY WRITTEN
21/08/2015
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/02/2015
LETTER OF SUSPENSION E-MAILED
06/02/2015
SUSPENSION LETTER WRITTEN
06/02/2015
TEAS/EMAIL CORRESPONDENCE ENTERED
05/02/2015
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/02/2015
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/02/2015
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/08/2014
NON-FINAL ACTION E-MAILED
04/08/2014
NON-FINAL ACTION WRITTEN
04/08/2014
ASSIGNED TO EXAMINER
04/08/2014
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/06/2014
NEW APPLICATION ENTERED
24/05/2014
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.